{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-23-001176","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.641047+00:00","generated_at":"2026-06-19T07:40:09.079768+00:00","sec_items":["1.01","2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"VolitionRx raises $7.525M in public offering of 4.3M shares plus full over-allotment","bullets":["Gross proceeds $7.525M from 4,300,000 shares at $1.75/share; net ~$8.0M after underwriting discount.","Underwriter exercised option for 645,000 additional shares, bringing total to 4,945,000 shares.","Proceeds to fund R&D, clinical studies, product commercialization, working capital, and potential acquisitions.","Preliminary unaudited cash and equivalents of ~$10.9M as of Dec 31, 2022.","Offering led by Newbridge Securities; closed Feb 22, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-23-001176","json":"https://secwatch.observer/filing/0001477932-23-001176.json","markdown":"https://secwatch.observer/filing/0001477932-23-001176.md","text":"https://secwatch.observer/filing/0001477932-23-001176.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793223001176/0001477932-23-001176-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793223001176/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T07:40:09.079768+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a6ba8b035d9485d8cc51c01f0c968b0f353a6d44","claim":"VOLITIONRX LTD entered into Underwriting Agreement with Newbridge Securities Corporation (effective 2023-02-17).","evidence_excerpt":"On February 17, 2023, VolitionRx Limited (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Newbridge Securities Corporation (the “Underwriter”) pursuant to which the Company agreed to issue and sell an aggregate of 4,300,000 shares","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/93314/000147793223001176/0001477932-23-001176-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Newbridge Securities Corporation"},{"label":"Effective","value":"2023-02-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}